Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01237951 · ClinicalTrials.gov registry record · Phase 2
High-Dose Gemcitabine, Busulfan and Melphalan With Hematopoietic-Cell Support for Patients With Poor-Risk Myeloma
A Phase 2 study, sponsored by M.D. Anderson Cancer Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 75
- Enrollment target
NCT01237951: Completed Phase 2 study, sponsored by M.D. Anderson Cancer Center.
NCT01237951 is a Phase 2 study that has completed, run by M.D. Anderson Cancer Center. The registered enrollment target is 75 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01237951, a Phase 2 study, has completed, sponsored by M.D. Anderson Cancer Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 75 participants
- Enrollment target
Study Summary
The goal of this clinical research study is to learn if the combination of gemcitabine, busulfan, and melphalan, when given before a stem cell transplant, can help to control refractory myeloma. The safety of this study treatment will also be studied.
Interventions
- DRUG Melphalan
- DRUG Busulfan
- DRUG Dexamethasone
- DRUG Gemcitabine
- DRUG Palifermin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 75 participants |
| Start Date | 2010-11-08 |
| Est. Completion | 2017-09-20 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01237951
The ClinicalTrials.gov registry entry for NCT01237951 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 75 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Melphalan is the first listed.
NCT01237951 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01237951 about?
NCT01237951 is a clinical study titled "High-Dose Gemcitabine, Busulfan and Melphalan With Hematopoietic-Cell Support for Patients With Poor-Risk Myeloma". The goal of this clinical research study is to learn if the combination of gemcitabine, busulfan, and melphalan, when given before a stem cell transplant, can help to control refractory myeloma. The safety of this study treatment will also be studied.
What is the current status of trial NCT01237951?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 75 participants. The study started on 2010-11-08. Estimated completion is 2017-09-20.
What interventions are being tested in trial NCT01237951?
The interventions under investigation include: Melphalan (DRUG), Busulfan (DRUG), Dexamethasone (DRUG), Gemcitabine (DRUG), Palifermin (DRUG).
Who is sponsoring clinical trial NCT01237951?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.